For Stock Exchange release at 7.00 a.m. Tuesday 8 February 2011
Victrex plc
AGM and Interim Management Statement
At the Annual General Meeting of Victrex plc to be held today, Chairman Anita Frew will make the following statement which comprises Victrex's Interim Management Statement covering the period from 1 October 2010 to date:
"We are pleased to report that Group sales volume for the 1st quarter ended 31 December 2010 amounted to 682 tonnes, a 43% increase over the 478 tonnes recorded in the same quarter in the previous financial year. This strong performance has continued through January 2011 to date. Although forward visibility on sales volumes remains limited, underlying trends are encouraging across all our major market segments. As was anticipated, gross margins have been maintained in-line with those of the second half of the financial year ended 30 September 2010.
The Group remains in an excellent financial position with a healthy balance sheet, strong cash generation, and no significant changes in the financial position of the Company since 30 September 2010."
The Company's trading update for the six months to 31 March 2011 will be issued on Thursday 7 April 2011.
Enquiries
Victrex plc
Anita Frew, Chairman 0203 128 8100 (8 February 2011)
David Hummel, Chief Executive 01253 897700 (thereafter)
Peter Bream, Finance Director
MHP Communications
Nick Denton / Barnaby Fry / Ian Payne 0203 128 8100
Victrex plc is an innovative world leader in high performance materials through the manufacture of VICTREX® PEEK™ polymer, a high performance, easy to process thermoplastic.
With over 30 years experience, Victrex is a global manufacturer of innovative, high performance thermoplastic polymers. We work with customers and end users to deliver technology driven solutions to the challenges and opportunities they face. Our Victrex Polymer Solutions division ('VPS') focuses on our transport, industrial and electronics markets and our Invibio Biomaterial Solutions division ('Invibio') focuses on providing specialist solutions for medical device manufacturers.